AIM
AMEX AIM ImmunoTech Inc.$0.1774 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.1774, and at the day’s high of $0.1815
- YTD change
- -84.30%
- vs 20-day SMA
- -9.43%
- vs 200-day SMA
- -69.03%
Price ranges
Price & Performance
-0.35 (-66.59%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.1% away from all-time highs of $20.3500
- AIM is down 84% since the beginning of the year
- AIM is down 93% over the past 12 months
- AIM is down 20% over the past 1 month
- 4% of all AIM investors are betting against AIM
- Number of investors short AIM has gone up 135% versus last month
AIM reads poor: price sits below both the 20- and 200-day averages, short interest is rising month over month, the 12-month move is -93.1%.
- Previous minute
- -$0.0009
- Last hour
- -$0.0009
- Last 5 days
- -1.44%
- vs 8-day SMA
- -2.63%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
